Skip to main contentAI and Advanced
/
SMSPHARMA · NSEBSE SENSEX74,294.96-0.03%BSE |
NIFTY 5023,346.4+0.33%NSE |
NIFTY BANK56,358.7+0.54%NSE |
NIFTY IT28,854.55-1.03%NSE |
NIFTY AUTO27,129-0.11%NSE |
NIFTY FMCG45,466.8-0.23%NSE |
NIFTY PHARMA26,710.1+0.49%NSE |
NIFTY 50022,840.55+0.82%NSE |
SM
NSE · Equity shares · Biotechnology & Drugs29.20 · 7.06%
SMS Pharmaceuticals SMSPHARMA
NSE:INR 442.95
BSE:INR 440.5
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SMSPHARMA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 413.75
Day rangeINR 403.25 — INR 418.55
52-week rangeINR 208.2 — INR 482
Volume6.71 L
Market cap3,349.21
P/E36.7
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)886.87
Net Income (INR Cr)101.99
Rev Growth (5 Year %)9.51
EPS Growth (5 Year %)8.58
P/E Ratio36.7
EPS11.15
Research path: Interpret SMS Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SMSPHARMASMS Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,362.44 | 1,152.68 | 1,034.09 |
| Cash Equivalents | 45.88 | Not available | Not available |
| Other Liabilities Total | 1.2 | 1.21 | 1.16 |
| Long Term Debt | 171.64 | 139.36 | 122.09 |
| Common Stock Total | 9.37 | 8.87 | 8.47 |
| Other Equity Total | 0 | 15.87 | 28.58 |
| Other Current Assets Total | 21.61 | 0.19 | 0.16 |
| Total Assets | 1,362.44 | 1,152.68 | 1,034.09 |
| Current Portof LT Debt/Capital Leases | 193.41 | 46.59 | 44.69 |
| Total Equity | 785.81 | 639.64 | 536.33 |
| Long Term Investments | 33.52 | 11.68 | 10.94 |
| Retained Earnings(Accumulated Deficit) | 776.44 | 545.09 | 429.47 |
| Total Common Shares Outstanding | 9.37 | 8.87 | 8.47 |
| Tangible Book Valueper Share Common Eq | 83.61 | 71.91 | 63.04 |
| Total Liabilities | 576.63 | 513.04 | 497.76 |
| Total Debt | 365.05 | 310.76 | 280.77 |
| Short Term Investments | 3.45 | 0.09 | 0.08 |
| Cashand Short Term Investments | 49.33 | 41.4 | 36.04 |
| Total Receivables Net | 215.87 | 219.15 | 250.17 |
| Deferred Income Tax | 50.82 | 48.1 | 42.8 |
| Accounts Receivable-Trade Net | 215.87 | 203.81 | 236.61 |
| Property/Plant/Equipment Total-Net | 652.86 | 565.52 | 464.87 |
| Minority Interest | 0 | 0 | Not available |
| Total Current Liabilities | 352.98 | 324.37 | 331.72 |
| Total Inventory | 351.21 | 286.68 | 242.27 |
| Accounts Payable | 120.43 | 113.92 | 151.32 |
| Other Currentliabilities Total | 39.13 | 29.37 | 20.9 |
| Total Long Term Debt | 171.64 | 139.36 | 122.09 |
| Intangibles Net | 2.8 | 2.13 | 2.66 |
| Other Long Term Assets Total | 35.26 | 9.89 | 7.86 |
| Total Current Assets | 638.01 | 554.47 | 533.89 |
| Accumulated Depreciation Total | Not available | -222.64 | -190.35 |
| Accrued Expenses | Not available | 9.69 | 0.82 |
| Prepaid Expenses | Not available | 7.05 | 5.25 |
| Additional Paid-In Capital | Not available | 69.82 | 69.82 |
| Cash | Not available | 41.31 | 35.96 |
| Property/Plant/Equipment Total-Gross | Not available | 753.49 | 624.95 |
| Notes Payable/Short Term Debt | Not available | 124.8 | 114 |
| Note Receivable-Long Term | Not available | 8.99 | 13.87 |
| Capital Lease Obligations | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio3.78
Price to Sale Ratio3.78
Growth
Debt 5Yr CAGR %7.47
Margins
Operating Margin 12m14.78
Operating Margin 5y Avg12.45
Net Profit Margin 12m9.97
Net Profit Margin 5y8.08
Yield
Dividend Yield %0.11
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk49.2
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions1
Strong Sell count0
Sell count0
Hold count0
Buy count1
Strong Buy count0
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 68.07%
- FII
- 0.65%
- MF
- 2.81%
- Other
- 28.47%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Corporate actions
Events
- dividendRs.0.4000 per share(40%)Final Dividend
- board MeetingsQuarterly Results
- board Meetings(Revised)
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.0.4000 per share(40%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for SMS Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
SMS Pharmaceuticals Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in the business of manufacturing active pharma ingredients and their intermediates. Its product categories include anti-ulcer, anti-inflammatory, anti-migraine, ant-diabetic, anti-coagulant, anti-viral, anti-retroviral, anti-psychotic, and others. The Company products include ranitidine, famotidine, pantoprazole sodium, itraconazole, lanoconazole, luliconazole, ibuprofen, Dex ibuprofen, fenoprofen calcium, sumatriptan, almotriptan, zolmitriptan, rizatriptan, Ele triptan, vildagliptin, sitagliptin, rosiglitazone, empagliflozin, dapagliflozin, tenofovir, dolutegravir, raltegravir, lamivudine, efavirenz, apixaban, rivaroxaban, levetiracetam, perampanel, lamotrigine, penciclovir, valaciclovir, and others. The Company has manufacturing facilities at Bachupally, Hyderabad, Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram District, Andhra Pradesh.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SMSPHARMA
- BSE Code
- 532815
Questions
Stock FAQ
What is the symbol and ISIN of SMS Pharmaceuticals?
SMS Pharmaceuticals has the symbol SMSPHARMA and ISIN - INE812G01025.
What is the current price of SMS Pharmaceuticals?
SMS Pharmaceuticals is currently trading at INR 442.95.
What are the year high and year low of SMS Pharmaceuticals?
SMS Pharmaceuticals has a year high of INR 482.00 and a year low of INR 208.20.
What is the market capitalization of SMS Pharmaceuticals?
SMS Pharmaceuticals has a market capitalization of INR 3,349.21 crore.
What is the P/E ratio of SMS Pharmaceuticals?
SMS Pharmaceuticals has a P/E ratio of 36.70.
What is the dividend yield of SMS Pharmaceuticals?
SMS Pharmaceuticals has a dividend yield of 0.11%.
How is the financial performance of SMS Pharmaceuticals based on revenue, net income, and EPS?
SMS Pharmaceuticals has revenue of INR 886.87 crore, net income of INR 101.99 crore, and EPS of INR 11.24.
What is the book value of SMS Pharmaceuticals?
SMS Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of SMS Pharmaceuticals?
SMS Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of SMS Pharmaceuticals?
SMS Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 3.78.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.